Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 4, Avril 2007
Page(s) 371 - 378
Section M/S revues
DOI https://doi.org/10.1051/medsci/2007234371
Publié en ligne 15 avril 2007
  1. Mestecky J, Lamm ME, Strober W, et al. Mucosal immunology, 3rd ed. San Diego: Academic Press, 2005 : 1868 p.
  2. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003; 3 : 331–41.
  3. Kelsall BL, Leon F. Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunology 2005; 6 : 132–48.
  4. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2 : 725–31.
  5. Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion and commitment. Immunol Rev 2001; 206 : 100–13.
  6. Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 2002; 32 : 1445–54.
  7. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 2003; 424 : 88–93.
  8. Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21 : 527–38.
  9. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005; 202 : 1063–73.
  10. Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202 : 1051–61.
  11. Lazarus NH, Kunkel EJ, Johnston B, et al. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 2003; 170 : 3799–805.
  12. Abonia JP, Hallgren J, Jones T, et al. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 2006; 108 : 1588–94.
  13. Quiding M, Nordstrom I, Kilander A, et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses, gamma-interferon production, and evokes local immunological memory. J Clin Invest 1991; 88 : 143–8.
  14. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997; 65 : 1387–94.
  15. Johansson EL, Wassén L, Holmgren J, et al. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001; 69 : 7481–6.
  16. Hornquist CE, Ekman L, Grdic KD, et al. Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J Immunol 1995; 155 : 2877–87.
  17. Goodrich ME, McGee DW. Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. Cytokine 1998; 10 : 948–55.
  18. Kunisawa J, Kiyono H. A marvel of mucosal T cells and secretory antibodies for the creation of first lines of defense, Cell Mol Life Sci 2005; 62 : 1308–21.
  19. Franco MA, Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 1995; 69 : 7800–6.
  20. Klavinskis LS, Bergmeier LA, Gao L, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996; 157 : 2521–7.
  21. Luci C, Hervouet C, Rousseau D, et al. Dendritic cell-mediated induction of cytotoxic responses following intravaginal immunization with the non-toxic B subunit of cholera toxin. J Immunol 2006; 176 : 2749–57.
  22. Simmons CP, Hussell T, Sparer T, et al. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol 2001; 166 : 1106–13.
  23. Ermak TH, Giannasca PJ, Nichols R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998; 188 : 2277–88.
  24. Wu HY, Weiner HL. Oral tolerance. Immunol Res 2003; 28 : 265–84.
  25. Stassen M, Fondel S, Bopp T, et al. Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol 2004; 34 : 1303–11.
  26. Hanninen A, Harrison LC. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 2000; 173 : 109–19.
  27. Crispe IN Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3 : 51–62.
  28. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 2005; 206 : 149–59.
  29. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005; 115 : 66–75.
  30. Anjuere F, Luci C, Lebens M, et al. In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin. J Immunol 2004; 173 : 5103–11.
  31. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11 : S45–53.
  32. Holmgen J, Adamsson J, Anjuere F, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005; 9 : 181–8.
  33. Chaillous L, Lefevre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 2000; 12 : 545–9.
  34. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16 : 183–200.
  35. Stanford M, Whittall T, Bergmeier LA, et al. Oral tolerization with peptide 336–351 linked to cholera toxin B subunit preventing relapses of uveitis in Behcet’s disease. Clin Exp Immunol 2004; 137 : 201–8.
  36. Tacket CO, Sztein MB, Losonsky GA, et al. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108 : 241–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.